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ORIGINAL ARTICLE 
MALE HYPOGONADISM AT A TERTIARY CARE HOSPITAL IN 
KARACHI, PAKISTAN 
Nanik Ram, Ali Asghar, Fauzan Hashmi, Najmul Islam 
Section of Endocrinology, Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan 
Background: Male hypogonadism is defined as ‘inadequate gonadal function, manifested by 
deficiency in gametogenesis and/or secretion of gonadal hormones’. Signs and symptoms of 
hypogonadism depend primarily on the age of onset. It can be classified according to the site 
primarily involved: the gonads, the hypothalamus, or the pituitary gland. The objective this study 
was to determine the presentation and aetiology of male hypogonadism seen in a tertiary care 
hospital. Methods: This cross-sectional study was conducted at Endocrine Clinics, Aga Khan 
University Hospital Karachi. Data of male patients with hypogonadism who attended clinics 
during January 2009 to August 2011 were reviewed. All male patients with clinical and 
biochemical evidence of hypogonadism were included in the study. Patients with Diabetes 
Mellitus, Metabolic Syndrome, Andropause, AIDS, Chronic Renal Failure, and Cirrhosis were 
excluded. Mean±SD were computed for quantitative variables. Frequency and percentages were 
computed for qualitative variables. Aetiology of male hypogonadism was categorised as primary 
and secondary hypogonadism. Results: A total of 85 patients with male hypogonadism attended 
the endocrine clinic. Mean age of patients was 25±10 years. Clinical presentations were small 
genitalia (65%), absent secondary sexual characteristics (53%), not attained puberty (47%), 
infertility (53%), erectile dysfunction (41%) and loss of libido (29%). Seventy-three (86%) 
patients had hypogonadotrophic hypogonadism (secondary hypogonadism) and 12 (14%) patients 
had hypergonadotrophic hypogonadism (primary hypogonadism). Among the patients with 
hypogonadotrophic hypogonadism 38 had idiopathic hypogonadotrophic hypogonadsim, 7 had 
pituitary adenoma, 6 had empty sella syndrome, 3 had Kallman’s syndrome, and 1 patient had 
haemosiderosis due to thalassaemia major; 18 patients did not undergo brain imaging. 
Conclusion: Small genitalia, absent secondary sexual characteristics and infertility were the main 
presenting features of hypogonad men. Majority of patients had hypogonadotrophic 
hypogonadsim. 
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INTRODUCTION 
Male hypogonadism is defined as ‘inadequate gonadal 
function, manifested by deficiency in gametogenesis 
and/or secretion of gonadal hormones’.1 It can be 
classified according to the site primarily involved in the 
hypothalamus-pituitary-gonadal axis. If the serum 
testosterone level is low and FSH and LH levels are 
elevated, the defect lies in the testis and 
hypergonadotropic hypogonadism is present. In these 
cases karyo type should be performed to rule out a 
chromosomal abnormality, such as Klinefelter’s 
syndrome (47, XXY; 46, XX; or 45, X/46, XY) which 
may occur in 10–15% of such patients. If testosterone is 
low and gonadotropins levels are low or normal, the 
patient has hypogonadotropic hypogonadism due to 
hypothalamic or pituitary disease.2 
A detailed history, physical examination and 
hormonal evaluation are required to diagnose male 
hypogonadism. In certain cases, further tests are needed 
to define the aetiology and the extent of Hypothalamic 
Pituitary Gland axis dysfunction. These include pituitary 
imaging studies, genetic studies, bone densitometry, 
testicular ultrasonography, testicular biopsy, hormonal 
dynamic testing and semen fluid analysis in those 
patients desiring fertility. 
Symptoms and signs of hypogonadism depend 
primarily on the age of onset. Before puberty patient 
may present with small testis, small phallus, scant pubic 
and axillary hairs, disproportionately long arms and legs 
and gynaecomastia. After puberty, signs and symptoms 
may include decrease in muscle mass, loss of libido, 
impotence, oligospermia or azoospermia, 
hypercholesterolemia and increase in visceral fat mass. 
Hypogonadism is often unrecognised before puberty 
unless it is associated with growth retardation or other 
anatomic or endocrine abnormalities. In most cases the 
first sign is delayed puberty, defined as ‘absence of 
secondary sexual characteristics at an age more than 
2SD above the population mean for the onset of 
puberty’.2–6 
Currently there are no studies from Pakistan on 
male hypogonadism.  In the West most common cause 
of male hypogonadism is primary hypogonadism, i.e., 
Klinefelter’s syndrome with the prevalence of 1:500, but 
we are seeing more cases of secondary hypogonadism 
(pituitary and hypothalamic) mostly idiopathic 
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hypogonadotrophic hypogonadism (IHH) in our 
practices which is unusual compared to West. 
The objective of this study was to determine 
the aetiology and presentation of male hypogonadism at 
a tertiary care hospital. 
MATERIAL AND METHODS 
This cross-sectional study was done at Endocrine 
Clinics of Aga Khan University Hospital Karachi. Data 
of male patients with hypogonadism who attended 
clinics during January 2009 to August 2011 were 
reviewed. Study was approved by Ethical Review 
Committee of the Hospital.  
All male patients with clinical and biochemical 
(serum AM testosterone level <200 ηg/dl) evidence of 
hypogonadism were included in the study. Patients with 
diabetes mellitus, metabolic syndrome, andropause, 
Acquired Immunodeficiency Syndrome (AIDS), 
chronic renal failure, and cirrhosis were excluded. 
Mean±SD were computed for quantitative 
variables like age etc. Frequency and percentages were 
computed for qualitative variables.  Aetiology of male 
hypogonadism was categorised as primary and 
secondary hypogonadism. 
RESULTS 
A total 85 patients with male hypogonadism attended 
the endocrine clinic. Mean age of patients was 25±10 
years. Clinical presentations were small genitalia 
(65%), absent secondary sexual characteristics (53%), 
not attained puberty (47%), infertility (53%), erectile 
dysfunction (41%) and loss of libido (29%). There was 
no history of substance/alcohol abuse among all 
patients. Among primary hypogonad patients, 3 had 
history of mumps. Among secondary hypogonad 
patients, 3 had anosmia/hyposmia (Table-1). 
Table-1: Clinical presentation of male 
hypogonadism in 85 patients 
Symptoms, Sign & History Frequency % 
Small Genitalia 55 65 
Absent Secondary Sexual Characteristics 45 53 
Infertility 45 53 
Not Attained Puberty 40 47 
Erectile dysfunction 35 41 
Loss of libido 25 29 
Family History 6 7 
History of Mumps 3 3.5 
Gynaecomastia 17 20 
Undescended Testis 14 16.5 
Anosmia/Hyposmia 3 3.5 
Seventy-three (86%) patients had 
hypogonadotrophic hypogonadism (secondary 
hypogonadism) and 12 (14%) patients had 
hypergonadotrophic hypogonadism (primary 
hypogonadism). Among the patients with 
hypogonadotrophic hypogonadism 38 (52%) had 
idiopathic hypogonadotrophic hypogonadsim (IHH), 7 
(9.6%) had pituitary adenoma, 6 (8.2%) had empty sella 
syndrome, 3 (4.1%) had Kallman’s syndrome based on 
presence of anosmia/hyposmia with normal MRI brain 
and one patient had hemosiderosis due to thalassaemia 
major, while 18 (24.65) patients did not undergo brain 
imaging (Table-2). Mean testosterone level in patients 
with IHH was 27.5±40 ηg/dL (Table-3) 
Table-2: Aetiology of male hypogonadism (n=85) 
Aetiology n (%) 
Hypogonadotrophic hypogonadism (Secondary 
hypogonadism)* 73 (86) 
Idiopathic hypogonadotrophic hypogonadism (IHH) 38 (52) 
Pituitary adenoma 7 (9.6) 
Empty sella syndrome 6 (8.2) 
Kallman’s syndrome 3 (4.1) 
Haemosiderosis (Thalassaemia Major) 1 (1.3) 
Hypergonadotrophic hypogonadism (Primary 
hypogonadism) 12 (14) 
*18 (24.65%) patients did not undergo MRI/Brain scan 
Table-3: Clinical and laboratory parameters in 38 
men with idiopathic hypogonadotrophic   
hypogonadism 
Parameters Mean±SD 
Age (years) 25±8.5 
Serum testosterone (ηg/dL) 27.5±40 
Follicle stimulating hormone (IU/L)            2.9±4.5 
Luteinizing hormone (IU/L) 1.9±2.1 
DISCUSSION 
In normal male, puberty is characterised by increased 
size of testis, increased penile length, 
spermatogenesis and appearance of secondary sexual 
characteristics under the influence of testosterone. 
We found small genitalia, absent secondary sexual 
characteristics and infertility the major presenting 
features which indicate pubertal deficiency of 
testosterone. Patients with total testosterone level less 
than 300 ηg/dL usually have signs and symptoms of 
classic hypogonadism.1 In our study hypo-
gonadotrophic hypogonadism was present in 86% of 
patients and majority among them had IHH defined 
as pubertal delay at 18 years of age or older, low 
testosterone level with low/normal FSH and LH 
levels and no pituitary or hypothalamic lesion. IHH is 
a disorder caused by genetic defect in biosynthesis 
and secretion of GnRH by hypothalamus or its action 
on pituitary. It is five times more prevalent in men.7 
Two thirds of patients with isolated GnRH deficiency 
have anosmia/hyposmia (called Kallman syndrome) 
and one third have normal sense of smell.8 Most 
cases of Kallman syndrome are sporadic,9 but 
familial occurrences is also observed. In our study, 
among hypogonadotrophic hypogonadism patients 3 
had Kallman syndrome. Specific genetic mutations, 
i.e., DAX-1, KAL-1, FGFR1, GPR54, Prop-1, and 
Hesx1, have been identified causing hypo-
gonadotrophic hypogonadism. 
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Our results concur with the study done by 
Citron et al, who found primary hypogonadism in 51 
patients, 164 patients had secondary hypogonadism 
among 238 patients with erectile dysfunction.10 In 
secondary hypogonadism group pituitary imaging was 
normal in 137 (83.5%) patients, empty sella and 
pituitary adenoma was found in 11 (6.7%) and 14 
(8.5%) patients respectively.10 
Secondary hypogonadism was not frequent in 
some case series of patients evaluated for erectile 
dysfunction, unless associated with 
hyperprolactinemia.11,12 Slag et al found 9% prevalence 
of secondary hypogonadism in 188 patients with 
impotency.13 In a study by Rhoden et al on pituitary 
imaging in male hypogonadism, MRI pituitary was 
normal in 74.5% of patients, partial empty sella in 
17.6% and pituitary microadenomas were found in 7.8% 
of patients, and like our study, 89% of patients younger 
than 40 years had normal MRI.14 
Klinefelter’s syndrome is the most common 
cause of primary hypogonadism. The fundamental 
chromosomal abnormality in Klinefelter’s syndrome is 
the presence of one or more extra X chromosomes. The 
principal karyotype in 90% of men with Klinefelter’s 
syndrome is 47, XXY. In adults, the most prominent 
clinical feature is very small testes size, <4 mL (<2.5 
cm) in length on clinical examination.15,16 In our study 
14% of patients had hypergonadotrophic hypogonadism 
(primary hypogonadism); among them 3 had history of 
mumps. Chromosomal analysis was not done in these 
patients of Klinefelter’s syndrome. Opioids and alcohol 
also cause male hypogonadism, in our study there was 
no history of substance abuse. 
The limitations of this study include 
retrospective study, limited number of patients, and no 
control group. Certain number of patients with 
hypogonadotrophic hypogonadism did not undergo 
brain imaging due to cost issue and were not followed 
up, so aetiology in these patients remained unknown. 
CONCLUSION 
Majority of hypogonad males have idiopathic 
hypogonadotrophic hypogonadism, further studies are 
needed to look at specific genetic mutations in IHH 
patients. 
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